Lung Therapeutics - About the company
Lung Therapeutics is an acquired company based in Austin (United States), founded in 2013. It operates as a Therapeutics for rare lung diseases include Pleural Effusion, Acute Lung Injury and Idiopathic Pulmonary Fibrosis.. Lung Therapeutics has raised $107M in funding from investors like Steelhead Capital Management, Austin Technology Incubator and Bios Partners. The company has 257 active competitors, including 70 funded and 89 that have exited. Its top competitors include companies like Moderna, BridgeBio and Spark Therapeutics.
Company Details
Lung Therapeutics is targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. Its current efforts are focused on a severe complication of pneumonia, called loculated pleural effusion, a condition where fluid has built up in the chest cavity surrounding the lungs and fibrinous scar tissue in the pleural cavity blocks fluid drainage. Its first product, LTI-01 (single chain urokinase plasminogen activator, or scuPA), is being studied for safe clearance of fibrinous scar tissue in patients with loculated pleural effusion. It has received more than $17M from NIH.
- Website
- lungtx.com
- Social
Key Metrics
Founded Year
2013
Location
Austin, United States
Stage
Acquired
Total Funding
$107M in 8 rounds
Latest Funding Round
Investors
Ranked
93rd among 257 active competitors
Exit Details
Acquired by Aileron Therapeutics (Oct 31, 2023)
Lung Therapeutics's acquisition details
Lung Therapeutics got acquired by Aileron Therapeutics on Oct 31, 2023. It was facilitated by Cozen O’Connor, Winston & Strawn and Clear Street.
Click here to take a look at Lung Therapeutics's acquisition in detail
Sign up to download Lung Therapeutics' company profile
Lung Therapeutics's funding and investors
Lung Therapeutics has raised a total funding of $107M over 8 rounds. Its first funding round was on Sep 10, 2014. Lung Therapeutics has 6 institutional investors.
Here is the list of recent funding rounds of Lung Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 04, 2022 | 6113521 | Series C | 1443048 | 3478475 | 4789086 | 3764114 |
Oct 31, 2019 | 1105090 | Series C | 2409608 | 5266456 | 9411491 | 7861306 |
May 24, 2019 | 2678706 | Series C | 3507706 | 7597176 | 2227994 | 4059486 |
Access funding benchmarks and valuations. Sign up today!View details of Lung Therapeutics's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Lung Therapeutics's Competitors and alternates
Top competitors of Lung Therapeutics include Moderna, BridgeBio and Spark Therapeutics. Here is the list of Top 10 competitors of Lung Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 80/100 | |
2nd |  BridgeBio 2015, Palo Alto (United States), Acquired | Developer of therapeutics for the treatment of genetic diseases | $434M | 77/100 | |
3rd | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 75/100 | |
4th | Rhythm Pharmaceuticals 2010, Boston (United States), Public | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | $84M | 72/100 | |
5th | PTC Therapeutics 1998, South Plainfield (United States), Public | Developer of small molecule drugs for the treatment of rare diseases | $248M | 68/100 | |
6th | Mereo BioPharma 2015, London (United Kingdom), Public | Developer of therapeutics for cancer and rare diseases | $119M | 68/100 | |
7th | Horizon Therapeutics 2008, Dublin (Ireland), Acquired | Developer of drugs for treating rare and autoimmune diseases | $61.8M | 68/100 | |
8th | BioCryst 1986, Durham (United States), Public | Developer of small molecule drugs for orphan & autoimmune diseases and antivirals | - | 65/100 | |
9th |  Design Therapeutics 2006, Carlsbad (United States), Public | Develops disease-modifying therapies for degenerative disorders | $171M | 64/100 | |
10th |  Amicus Therapeutics 2002, Philadelphia (United States), Public | Developer of therapies for rare and orphan diseases | $91M | 64/100 | |
93rd | Lung Therapeutics 2013, Austin (United States), Acquired | Therapeutics for rare lung diseases include Pleural Effusion, Acute Lung Injury and Idiopathic Pulmonary Fibrosis. | $107M | 40/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Lung Therapeutics's competitors? Click here to see the top ones
Lung Therapeutics's Investments and acquisitions
Lung Therapeutics has made no investments or acquisitions yet.
Reports related to Lung Therapeutics
Here is the latest report on Lung Therapeutics's sector:
News related to Lung Therapeutics
Filter this list•
Aileron Therapeutics Announces Acquisition of Lung TherapeuticsTullahoma News•Nov 01, 2023•Aileron Therapeutics, Lung Therapeutics
•
Lung Therapeutics Announces Successful Completion of Phase 1a Clinical Trial of LTI-03 in Healthy VolunteersBusiness Wire•Mar 22, 2022•Lung Therapeutics
•
Lung Therapeutics, Inc. Strengthens Board of Directors with Appointment of Biopharmaceutical Veteran William C. FaireyBusiness Wire•Aug 31, 2021•Lung Therapeutics, ChemoCentryx
•
Lung Therapeutics Announces Appointment of Sharon Morriss, PhD, as Senior Vice President of Clinical DevelopmentBusiness Wire•Jul 13, 2021•Lung Therapeutics
•
Lung Therapeutics Announces Appointment of Cory M. Hogaboam, Ph.D., as Chief Scientific OfficerBusiness Wire•Apr 13, 2021•Lung Therapeutics
•
Taiho and Lung Therapeutics Enter Into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural EffusionsBusiness Wire•Nov 12, 2020•Taiho Pharmaceuticals, Lung Therapeutics
•
Lung Therapeutics Receives SBIR Award for Kidney Fibrosis Research; Principal Investigator BreAnne Mackenzie Will Speak at 4th Annual IPF Summit 2020/DigitalBusiness Wire•Aug 21, 2020•Lung Therapeutics
•
Lung Therapeutics, Inc. Raises $36 Million in Series C Financing to Advance Clinical PipelineBusiness Wire•Jun 04, 2019•Lung Therapeutics
•
Lung Therapeutics, Inc. Announces New Chief Financial Officer and Board MemberBusiness Wire•Feb 04, 2019•Lung Therapeutics
•
Lung Therapeutics Gets $14.3MTexasTechPulse•Jun 06, 2017•Lung Therapeutics, Bios Partners, UT Horizon Fund
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Lung Therapeutics
Explore our recently published companies
- North Sky Farm - Walworth based, 2021 founded, Funding Raised company
- Lil' Red's Boiled Peanuts - San Antonio based, 2016 founded, Funding Raised company
- Ranch House Meat - Billings based, 2023 founded, Funding Raised company
- Underground Tap Grill - Edmonton based, 2012 founded, Public company
- Transport Rl - 1996 founded, Unfunded company
- Cactus TEFL - United Kingdom based, 2004 founded, Unfunded company
